Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics in Ustekinumab Responders Versus Non-responders

NCT05270733 is registered in ClinicalTrials.gov with University Hospitals Cleveland Medical Center as lead sponsor.

NCT NCT05270733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05270733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics in Ustekinumab Responders Versus Non-responders
Lead sponsor
University Hospitals Cleveland Medical Center
Phase
Phase 4
Overall status
Recruiting
Start date
November 10, 2022
Completion date
December 31, 2026
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis